Uveitis clinical trials
The registry lists 299 studies for Uveitis across more than 10 countries. 32 are recruiting or about to start. 212 of them are mainly about Uveitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its 7 narrower conditions too, such as Behcet Syndrome: 482 studies, 87 open.
Get an email when these change. Save the Uveitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Eye Institute (NEI) (42) · Novartis Pharmaceuticals (9) · Assistance Publique - Hôpitaux de Paris (8) · St. Franziskus Hospital (8) · Oregon Health and Science University (7) · Assiut University (6) · University of California, San Francisco (6) · Sun Yat-sen University (5)
What is being tested here
Drugs under test in Uveitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Adalimumab | 2 | 6 | 12 |
| Methotrexate | 1 | 4 | 7 |
| Allogeneic Regulatory T-cells TRX103 | 1 | 0 | 1 |
| FXS5626 | 1 | 0 | 1 |
| GENSCI048 | 1 | 0 | 1 |
| Minocycline | 1 | 0 | 1 |
| Triamcinolone | 0 | 4 | 8 |
| Secukinumab | 0 | 7 | 8 |
| Triamcinolone Acetonide | 0 | 4 | 7 |
| Daclizumab | 0 | 0 | 6 |
Drug classes tested here Antimetabolites 1 open · Corticosteroids 18 · Angiogenesis inhibitors 6 · JAK inhibitors 4 · Tyrosine kinase inhibitors (TKIs) 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8
- Nov 2026"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease" · Assistance Publique - Hôpitaux de Paris
- Nov 2026Metagenomics for Ocular Inflammation · Moorfields Eye Hospital NHS Foundation Trust
- Dec 2026Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis · Peking Union Medical College Hospital
- Feb 2027PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCT · Sheffield Children's NHS Foundation Trust
- Feb 2027A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Apr 2027A Study of Uveitis in Children <18 Years of Age · Jaeb Center for Health Research
- Apr 2027Imaging Quantification of Inflammation (IQI) · The Cleveland Clinic
- Sep 2027Ocular Fluid Work-up in Presumed Trematode Induced Granulomatous Uveitis · Kasr El Aini Hospital
Who these studies take
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger. 10 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (18%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 10 (45%) | 10 (45%) |
| 18 | 18 (82%) | 18 (82%) |
| 30 | 18 (82%) | 18 (82%) |
| 40 | 18 (82%) | 18 (82%) |
| 50 | 18 (82%) | 18 (82%) |
| 65 | 18 (82%) | 18 (82%) |
| 75 | 13 (59%) | 13 (59%) |
| 85 | 13 (59%) | 13 (59%) |
Across all 299 studies, recruiting or not: 18% stop at 75 or younger and 13% at 65; 34% take children; <1% are for women only and 0% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Uveitis studies take
Of 17 phase 2 interventional studies under Uveitis, half reached primary completion within 28 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 28 mo20–37 · 17 studies | — | — |
| Phase 3 | 41 mo26–55 · 15 studies | — | — |
| Interventional, no phase | 27 mo9–49 · 16 studies | — | — |
| Observational | 77 mo28–143 · 32 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting1
Stopped1
- Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious UveitisTerminatedNov 2, 2026NCT02706704
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 299. Browse all 299 → or search them.
- A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious UveitisRecruitingNCT07427628Phase 11 country
- A Study of Uveitis in Children <18 Years of AgeRecruitingNCT075181341 country
- The Microbiome in Uveitis and Pediatric Inflammatory DiseasesNot yet recruitingNCT078855011 country
- Ocular Fluid Work-up in Presumed Trematode Induced Granulomatous UveitisRecruitingNCT078851371 country
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIURecruitingNCT07552012Phase 21 country
- PANDA-ASOCT: Paediatric Anterior Uveitis Detection With Automated Image Analysis Using ASOCTRecruitingNCT078135981 country
- A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.RecruitingNCT07547995Phase 21 country
- Metagenomics for Ocular InflammationRecruitingNCT069741621 country
- A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque PsoriasisRecruitingNCT07663331Phase 41 country
- Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic UveitisNot yet recruitingNCT06390436Phase 41 country
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruitingNCT05651880Phase 31 country
- Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome PatientsRecruitingNCT06395285Phase 13 countries
- RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric AgeRecruitingNCT062737485 countries
- Genetics of UveitisRecruitingNCT023572381 country
- Analysis of Anterior Chamber Inflammation by Optical Coherence TomographyRecruitingNCT017465371 country
- Wide Field OCTA in Ocular DiseasesNot yet recruitingNCT07298174
- AutoInflammatory Disease Alliance Registry (AIDA)RecruitingNCT0520071522 countries
- Demographic Data and Clinical Presentation of Pediatric UveitisNot yet recruitingNCT06920017
- Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.RecruitingNCT06539481Phase 43 countries
- The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic ConjunctivitisEnrolling by invitationNCT05839938Not applicable1 country
- A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious UveitisRecruitingNCT055927171 country
- Lyon Uveitis StudyRecruitingNCT038775751 country
- Lyon Sarcoid Uveitis CohortRecruitingNCT038637821 country
- Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) PositiveRecruitingNCT040880191 country
- Optical Coherence Tomography (OCT) in UveitisRecruitingNCT020261281 country
- Relevance and Efficiency of SecOnd Line Workup for UveitisNot yet recruitingNCT06102408
- Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior UveitisRecruitingNCT04798755Phase 31 country
- Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiSNot yet recruitingNCT05928754Not applicable
- "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"Not yet recruitingNCT05874505Phase 2
- Minocycline for Chronic Autoimmune UveitisRecruitingNCT05474729Phase 1/21 country
- Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's UveitisNot yet recruitingNCT05105347Phase 4
- Acute and Chronic Inflammatory Disease, Lifestyle and Treatment ResponseRecruitingNCT041930201 country
- Uveitis/Intraocular Inflammatory Disease Biobank (iBank)CompletedNCT026563811 country
- Intestinal Bacteria and Ocular Inflammatory DiseaseCompletedNCT018592991 country
- Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular EdemaActive, not recruitingNCT05608837Phase 21 country
- Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION StudyCompletedNCT06161415Phase 11 country
- Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious UveitisTerminatedNCT02706704Phase 21 country
- Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior UveitisCompletedNCT07869953Phase 1/21 country
- Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)CompletedNCT05180526Phase 41 country
- The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentCompletedNCT05486468Phase 31 country
- Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mgCompletedNCT078493091 country
- The Cohort Study of Uveitis PatientsCompletedNCT057275401 country
- Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious UveitisCompletedNCT06310837Not applicable1 country
- Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With UveitisCompletedNCT05388838Not applicable1 country
- An Interventional Study of Upadacitinib Extended-Release Tablets in Patients With Refractory UveitisActive, not recruitingNCT07773623Phase 41 country
- A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsTerminatedNCT07218770Phase 1/21 country
- Ocular Pathogen and Transcriptome Investigation Using Comprehensive SequencingCompletedNCT05286203Not applicable1 country
- A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingNCT04088409Phase 35 countries
- Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory DiseasesCompletedNCT06585670Not applicable1 country
- Imaging Quantification of Inflammation (IQI)Active, not recruitingNCT047046091 country